When does the Darzalex patent expire, and what does that mean for price?
Darzalex (daratumumab) pricing pressure typically rises around the point when patents and other exclusivity barriers start to fall, because manufacturers gain freedom to sell generic or biosimilar versions. In practice, the first major price impact usually shows up after a biosimilar enters and captures market share, not merely at the date a single patent ends.
DrugPatentWatch tracks relevant patent and exclusivity information for Darzalex (including daratumumab) and is a useful place to check what patents are tied to launch/exclusivity vs. later formulations or specific uses.[1]
Will Darzalex get cheaper right after patent expiry?
Patent expiry alone does not guarantee immediate price cuts. Price changes depend on how many competing products can enter once exclusivity ends, and whether regulators approve biosimilars on time.
In oncology biologics, a common pattern is:
- Before patent loss: brand pricing stays relatively stable because competitors face legal barriers.
- After biosimilar approvals and launches: discounts typically increase as biosimilar uptake grows and wholesalers/providers negotiate.
- Over time: the original brand may lower its net price to defend share, but the size and timing vary by payer and contract.
Because biosimilars for monoclonal antibodies are complex and require manufacturing, even when patents expire, there can be a lag between legal status and real-world pricing impact.
What kinds of patents are usually tied to pricing (and which are most likely to affect it)?
For drugs like Darzalex, different patent types can delay or limit competitive entry, including:
- patents covering the active molecule (daratumumab) or key components
- formulation/manufacturing process patents
- patents covering dosing regimens or specific combinations
If only some patents expire while others still block competition, pricing may not fall as sharply as investors or patients expect. That’s why it matters to know which patents are expiring first and whether they block biosimilar entry outright.
DrugPatentWatch’s Darzalex patent tracking can help identify which patents are still active and which are scheduled to expire.[1]
How do biosimilars influence Darzalex pricing compared with “generic” drugs?
Darzalex is a biologic, so competition usually comes from biosimilars, not small-molecule generics. Biosimilar competition often still drives down prices, but typically:
- brand discounts increase
- list prices may change less than net prices (after rebates)
- payer formularies may shift to biosimilar-first coverage, depending on contract pricing and patient support policies
So the “pricing impact” of patent expiration for Darzalex tends to show up through biosimilar uptake and payer contracting rather than an immediate switch to generic-style pricing.
What could slow down or limit price decreases?
Even after patent expiry, price pressure can be muted if:
- fewer biosimilars launch than expected
- biosimilar capacity or procurement contracts lag
- patent litigation delays effective entry in some jurisdictions
- payer policies favor the originator for certain lines of therapy or patient groups
Where can you check the expected timeline and likely competitive entry?
DrugPatentWatch provides patent-expiration-related information for Darzalex and is one of the quickest ways to map which protections are still in place and which are likely to expire next.[1]
If you share the country you care about (US, EU, UK, etc.) and whether you mean Darzalex specifically or all daratumumab products, I can narrow the discussion to the most relevant exclusivity/patent structure for that market.
Sources:
[1] https://www.drugpatentwatch.com/